Production of Cannabinoids via Extraction, Chemical Synthesis and Especially Biotechnology
2,000 € – 10,000 € ex. tax
Huge market potential for CBD and other cannabinoids – how best to produce them?
Cannabis removed from the UN prohibition schedule and CBD not considered as a narcotic drug – Two major decisions to drive further research to explore the full potential of one of the major and longest established medicinal plants
The new report “Production of Cannabinoids via Extraction, Chemical Synthesis and Especially Biotechnology – Current Technologies, Potential & Drawbacks and Future Development” provides all information on production technologies, medical applications and political framework conditions. The Report will guide you through the complex synthesis of cannabinoids, state-of-the-art methods for extraction and production and will extensively show the major hidden potential and synergistic effects of biotechnological cannabinoid production. The report is aimed at experts in the pharmaceutical and biotech industry and provides deep insights into (bio)chemical reactions, processes and producers. The main authors are biotechnology experts and physicians from the nova-Institute, Dr. Pia Skoczinski and Dr. med. Franjo Grotenhermen, and the chemist Dr. rer. nat. Bernhard Beitzke, who has been advising the “European Industrial Hemp Association” (EIHA) as an expert for years. The 142-page technology report provides in-depth information on established and emerging biotechnological approaches on the production of cannabinoids, as well as an overview on the state-of-the-art production methods using plant extraction and chemical synthesis. An extensive description of pharmacological effects, therapeutic potential and medicinal applications for ∆9-tetrahydrocannabinol (∆9-THC) and cannabidiol (CBD), together with a short excursus on the EU regulatory framework for cannabinoids, conclude this comprehensive study. Additionally, 59 companies active in cannabinoid production are listed, from which 20 specialised in biotechnological production and chemical synthesis are described in detail.
Single-Site-Licence: Up to five (5) users of the Customer can access the study within one location for their own operational purposes.
Enterprise-Licence: The Customer and all subsidiaries can access the study at all company locations for their own operational purposes. Includes one hour Q&A with nova-experts.
